RU2008147269A - Применение органических соединений - Google Patents
Применение органических соединений Download PDFInfo
- Publication number
- RU2008147269A RU2008147269A RU2008147269/14A RU2008147269A RU2008147269A RU 2008147269 A RU2008147269 A RU 2008147269A RU 2008147269/14 A RU2008147269/14 A RU 2008147269/14A RU 2008147269 A RU2008147269 A RU 2008147269A RU 2008147269 A RU2008147269 A RU 2008147269A
- Authority
- RU
- Russia
- Prior art keywords
- disease
- pharmaceutical composition
- errγ
- diabetes
- treatment
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000000556 agonist Substances 0.000 claims abstract 11
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 8
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract 5
- 208000023105 Huntington disease Diseases 0.000 claims abstract 5
- 208000018737 Parkinson disease Diseases 0.000 claims abstract 5
- 230000004770 neurodegeneration Effects 0.000 claims abstract 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract 5
- 206010022489 Insulin Resistance Diseases 0.000 claims abstract 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims abstract 4
- 208000008589 Obesity Diseases 0.000 claims abstract 4
- 206010033307 Overweight Diseases 0.000 claims abstract 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims abstract 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract 4
- 208000016097 disease of metabolism Diseases 0.000 claims abstract 4
- 208000030159 metabolic disease Diseases 0.000 claims abstract 4
- 235000020824 obesity Nutrition 0.000 claims abstract 4
- 150000003839 salts Chemical class 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000032928 Dyslipidaemia Diseases 0.000 claims 4
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims 3
- 238000004458 analytical method Methods 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000004153 glucose metabolism Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000037081 physical activity Effects 0.000 claims 2
- IKPPIUNQWSRCOZ-WOJGMQOQSA-N GSK 4716 Chemical group C1=CC(C(C)C)=CC=C1\C=N\NC(=O)C1=CC=C(O)C=C1 IKPPIUNQWSRCOZ-WOJGMQOQSA-N 0.000 claims 1
- 108091008577 estrogen receptors gamma Proteins 0.000 claims 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims 1
- WLKOCYWYAWBGKY-UYRXBGFRSA-N n-[(z)-[4-(diethylamino)phenyl]methylideneamino]-4-hydroxybenzamide Chemical compound C1=CC(N(CC)CC)=CC=C1\C=N/NC(=O)C1=CC=C(O)C=C1 WLKOCYWYAWBGKY-UYRXBGFRSA-N 0.000 claims 1
- 230000037080 exercise endurance Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79722806P | 2006-05-03 | 2006-05-03 | |
| US60/797,228 | 2006-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008147269A true RU2008147269A (ru) | 2010-06-10 |
Family
ID=38477124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008147269/14A RU2008147269A (ru) | 2006-05-03 | 2007-05-02 | Применение органических соединений |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090281191A1 (https=) |
| EP (1) | EP2015777B1 (https=) |
| JP (1) | JP2009535425A (https=) |
| KR (1) | KR20090005137A (https=) |
| CN (1) | CN101432024A (https=) |
| AT (1) | ATE477819T1 (https=) |
| AU (1) | AU2007248112A1 (https=) |
| BR (1) | BRPI0711174A2 (https=) |
| CA (1) | CA2649701A1 (https=) |
| DE (1) | DE602007008553D1 (https=) |
| MX (1) | MX2008014008A (https=) |
| RU (1) | RU2008147269A (https=) |
| WO (1) | WO2007131005A2 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| US8962546B2 (en) * | 2011-03-01 | 2015-02-24 | Salk Institute For Biological Studies | Modulation of estrogen receptor-related receptor gamma (ERRγ) and uses therefor |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9714946B2 (en) | 2013-03-14 | 2017-07-25 | Dana-Farber Cancer Institute, Inc. | Bromodomain binding reagents and uses thereof |
| EP3010587A4 (en) * | 2013-06-18 | 2017-04-12 | Salk Institute for Biological Studies | Methods of treating muscular dystrophy |
| AU2014292888B2 (en) | 2013-07-25 | 2018-03-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| BR112016017045A2 (pt) | 2014-01-31 | 2017-08-08 | Dana Farber Cancer Inst Inc | Derivados de diazepano e usos dos mesmos |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
| EP3739041A1 (en) | 2014-03-27 | 2020-11-18 | The Salk Institute for Biological Studies | Compositions and methods for treating type 1 and type 2 diabetes and related disorders |
| KR20170032474A (ko) * | 2014-08-08 | 2017-03-22 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
| AU2016225076B2 (en) | 2015-02-27 | 2018-09-13 | Salk Institute For Biological Studies | Reprogramming progenitor compositions and methods of use therefore |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| WO2017053084A1 (en) * | 2015-09-25 | 2017-03-30 | Salk Institute For Biological Studies | Estrogen related receptor gamma (erry) enhances and maintains brown fat thermogenic capacity |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| AU2017269364B2 (en) | 2016-05-25 | 2023-08-31 | Salk Institute For Biological Studies | Compositions and methods for organoid generation and disease modeling |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2466415C (en) * | 2001-11-09 | 2020-01-21 | Dana-Farber Cancer Institute, Inc. | Pgc-1.beta., a novel pgc-1 homologue and uses therefor |
| WO2004015415A1 (ja) * | 2002-08-08 | 2004-02-19 | Japan Science And Technology Agency | 薬剤スクリーニング方法 |
| US20050074765A1 (en) * | 2002-10-16 | 2005-04-07 | Blanchard Steven G. | Methods for identifying and using modulators of estrogen related receptor gamma |
| WO2006130503A2 (en) * | 2005-05-27 | 2006-12-07 | Janssen Pharmaceutica N.V. | Errϝ peptide fragment complexes and uses thereof in drug discovery |
-
2007
- 2007-05-02 RU RU2008147269/14A patent/RU2008147269A/ru not_active Application Discontinuation
- 2007-05-02 CA CA002649701A patent/CA2649701A1/en not_active Abandoned
- 2007-05-02 WO PCT/US2007/067971 patent/WO2007131005A2/en not_active Ceased
- 2007-05-02 CN CNA2007800155975A patent/CN101432024A/zh active Pending
- 2007-05-02 EP EP07783060A patent/EP2015777B1/en not_active Revoked
- 2007-05-02 KR KR1020087026812A patent/KR20090005137A/ko not_active Withdrawn
- 2007-05-02 JP JP2009510039A patent/JP2009535425A/ja active Pending
- 2007-05-02 US US12/299,256 patent/US20090281191A1/en not_active Abandoned
- 2007-05-02 AT AT07783060T patent/ATE477819T1/de not_active IP Right Cessation
- 2007-05-02 AU AU2007248112A patent/AU2007248112A1/en not_active Abandoned
- 2007-05-02 DE DE602007008553T patent/DE602007008553D1/de active Active
- 2007-05-02 MX MX2008014008A patent/MX2008014008A/es not_active Application Discontinuation
- 2007-05-02 BR BRPI0711174-6A patent/BRPI0711174A2/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP2015777A2 (en) | 2009-01-21 |
| US20090281191A1 (en) | 2009-11-12 |
| WO2007131005A3 (en) | 2008-06-19 |
| MX2008014008A (es) | 2009-03-25 |
| BRPI0711174A2 (pt) | 2011-08-23 |
| JP2009535425A (ja) | 2009-10-01 |
| DE602007008553D1 (de) | 2010-09-30 |
| WO2007131005A2 (en) | 2007-11-15 |
| AU2007248112A1 (en) | 2007-11-15 |
| CA2649701A1 (en) | 2007-11-15 |
| KR20090005137A (ko) | 2009-01-12 |
| EP2015777B1 (en) | 2010-08-18 |
| ATE477819T1 (de) | 2010-09-15 |
| CN101432024A (zh) | 2009-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008147269A (ru) | Применение органических соединений | |
| Mercadante et al. | Pharmacological management of cancer pain in the elderly | |
| Khan et al. | A randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder | |
| Ginsberg et al. | L-methylfolate plus SSRI or SNRI from treatment initiation compared to SSRI or SNRI monotherapy in a major depressive episode | |
| Kim et al. | Safety, tolerability, and efficacy of metformin extended‐release oral antidiabetic therapy in patients with type 2 diabetes: An observational trial in Asia | |
| Yasuda et al. | Superiority of duloxetine to placebo in improving diabetic neuropathic pain: Results of a randomized controlled trial in Japan | |
| Hoy | Lorcaserin: a review of its use in chronic weight management | |
| JP2013516488A (ja) | 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療 | |
| Leo et al. | Atypical antipsychotic use in the treatment of psychosis in primary care | |
| Canal et al. | A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses | |
| Meng et al. | Trends in psychotropic use in Saskatchewan from 1983 to 2007 | |
| Lowry et al. | Pediatric pharmaceutical ingestions | |
| Park et al. | The efficacy of tramadol/acetaminophen combination tablets (Ultracet®) as add-on and maintenance therapy in knee osteoarthritis pain inadequately controlled by nonsteroidal anti-inflammatory drug (NSAID) | |
| US20260102370A1 (en) | Methods of treating obesity in responder and non-responder populations | |
| Müller | Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson’s disease | |
| Waters | Treatment of advanced stage patients with Parkinson's disease | |
| US20160022659A1 (en) | Methods for treating attention deficit hyperactivity disorder using a combination of bupropion ((±)-2-(tert-butylamino)-1-(3-chlorophenyl)propan-1-one) and phentermine (2-methyl-1-phenylpropan-2-amine) | |
| CN1950084A (zh) | 用于治疗慢性心力衰竭的哌克昔林 | |
| Chiu et al. | Olanzapine in Chinese treatment‐resistant patients with schizophrenia: An open‐label, prospective trial | |
| Ramachandran et al. | Pharmacokinetics of anti-tuberculosis drugs in children | |
| Day et al. | Serotonin syndrome in a patient taking Lexapro and Flexeril: a case report | |
| Chiu et al. | Rapid weight gain during mirtazapine treatment | |
| de Biase et al. | ADMET considerations for restless leg syndrome drug treatments | |
| CN104147036B (zh) | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 | |
| Gambassi et al. | Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20100622 |